Drug intelligence / Profile preview

diazoxide

Development stage: Approved
Lead developer: Merck
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Diazoxide is a small molecule, nondiuretic benzothiadiazine derivative used primarily to manage hypoglycemia due to hyperinsulinism. It acts by opening ATP-sensitive potassium channels on pancreatic beta cells, leading to membrane hyperpolarization and inhibition of insulin release. This results in increased blood glucose levels. Diazoxide is also used intravenously for hypertensive emergencies as a vasodilator and has been studied for use in Prader-Willi syndrome (as diazoxide choline) to treat hyperphagia. It is chemically related to thiazide diuretics but lacks significant diuretic activity[1][3][5].

Brand names: ProglycemHyperstatVykat XR
Other names: diazoxide choline (for the choline salt/extended-release formulation)

Targets

KATP channel (ATP-sensitive potassium channel)

Beyond the preview

Go deeper on diazoxide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on diazoxide.

Explore the full profile